San Diego, California, USA
With the goal of creating a company well-positioned to unlock the potential of blood, CaridianBCT and Terumo Transfusion—operating independently until spring 2012—plan to seamlessly combine people, products and processes in an ongoing drive to improve customer efficiencies and patient outcomes.
Terumo BCT will bring together two industry leaders, CaridianBCT and Terumo Transfusion, both strongly focused on customers and patients with a shared passion for innovation and a commitment to developing and delivering customer quality and satisfaction. The combined organization will provide a wider range of automated collections, manual and automated whole blood processing and pathogen reduction solutions, combined with therapeutic apheresis and cell processing technologies.
“Unlocking the potential of blood is our commitment to the blood banking and transfusion medicine industry, to our customers and to the patients we ultimately serve. It is a never ending quest to bring forward scientific advances and innovation. We can only do this through close collaboration with our customers and listening to their invaluable insights and advice,” said David Perez, Terumo BCT President and CEO and Chairman of the Terumo Blood Management Business Board. “Drawing from both companies, we will bring together the industry’s best people, products and processes to deliver on this commitment, as well as to unlock the potential of our customers’ business and the treatment options that target improved customer efficiencies and patient outcomes.”
During the integration period, customers can expect to interact with each company as they always have, continuing to partner with their respective company representatives and service personnel. CaridianBCT and Terumo Transfusion are working to complete the majority of the integration by April 1, 2012, and until such time, will operate as two independent businesses. “I am delighted to announce that we have been moving quickly, but thoughtfully on our integration planning, and I’m pleased with the progress we have made as we implement our plans,” Perez said. “When our integration is complete, Terumo BCT will focus its long-term vision on increasing the value of every donation, expanding the number of treatment options for patients and enabling scalable production of cell therapies. Our goal is to continue creating value through innovation and integration, together with our customers.”
Tokyo-based Terumo Corporation closed the acquisition of CaridianBCT on April 13, 2011, and immediately began implementing a plan to integrate its transfusion business and CaridianBCT—to create Terumo BCT. Terumo BCT will be the first company in Terumo’s Global Blood Management business, and will maintain its global headquarters in Lakewood, Colorado, U.S. The new organization will continue to serve a range of customers, including blood centers, hospitals, therapeutic apheresis centers, and biotech and cell processing.
CaridianBCT and Terumo Transfusion are becoming Terumo BCT, the world leader in blood component technology. The companies’ products and services are designed to set new levels of performance today, and their innovation pipeline strives to substantially improve blood collection and processing, blood therapies and the development of cell therapies in the years ahead.
Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with $4 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan’s leading stock index.
This is HCP only content